CNS‐active drugs for neuropsychiatric disorders differentially modulate the risk of AD development

Collectively, these results indicate that antidepressants, sedatives, anticonvulsants, and stimulants are beneficial as risk modifiers for AD, while antipsychotics appear to increase the vulnerability of the brain to AD development. The potential use of combination therapy with antipsychotics could mitigate the risk conferred by these drugs. These findings have the potential to contribute to advancing neuropsychiatric treatment that could impact the risk of Alzheimer's disease.